利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.023 秒)

    Compositions for preventing hormone induced adverse effects
    1.
    发明授权
    Compositions for preventing hormone induced adverse effects 有权
    用于预防激素诱发的不良反应的组合物

    公开(公告)号：US07144586B2

    公开(公告)日：2006-12-05

    申请号：US09799251

    申请日：2001-03-05

    申请人： Joseph Levy ,  Yoav Sharoni

    发明人： Joseph Levy ,  Yoav Sharoni

    IPC分类号： A61K9/20 ,  A61K31/56 ,  A01N45/00

    CPC分类号： A61K31/565 ,  A61K31/015 ,  A61K31/07 ,  A61K31/56 ,  A61K31/57 ,  A61K33/24 ,  A61K36/185 ,  A61K31/12 ,  A61K31/01 ,  A61K2300/00

    摘要： A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein the carotenoid is in an amount effective to prevent the adverse effects which may result from the administration of the hormone.

    摘要翻译： 适用于每天一次给予人的单位剂型，其包含生理有效量的至少一种选自甾体雌激素，雌二醇，雌酮，甲羟孕酮，炔诺酮，炔诺酮，孕激素，甲炔炔酮和孕酮的激素， 至少一种类胡萝卜素，其中类胡萝卜素具有有效预防可能由激素给药引起的副作用的量。

    CAROTENOID OXIDATION PRODUCTS AS CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC AGENTS
    2.
    发明申请
    CAROTENOID OXIDATION PRODUCTS AS CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC AGENTS 审中-公开
    CAROTENOID氧化产品作为化学和化学药剂

    公开(公告)号：US20090069417A1

    公开(公告)日：2009-03-12

    申请号：US12090174

    申请日：2006-10-05

    申请人： Yoav Sharoni ,  Joseph Levy ,  Yoram Sela ,  Zohar Nir

    发明人： Yoav Sharoni ,  Joseph Levy ,  Yoram Sela ,  Zohar Nir

    IPC分类号： A61K31/343 ,  A61K31/01 ,  A61K31/045 ,  A61K31/11 ,  A61P35/00 ,  A61K31/12 ,  A61K31/336

    CPC分类号： A61K31/203 ,  A61K31/366

    摘要： The present invention relates to a method for the chemoprevention and treatment of cancer, by administering a pharmaceutical composition comprising a carotenoid derivative, such as a derivative of lycopene, a- and b-carotene, phytoene, phytofluene, lutein, zeaxanthin, α- and β-cryptoxanthin, canthaxanthin, astaxanthin, or other carotenoid. The carotenoid derivative is a carotenoid oxidation product, and is preferably an aldehyde derivative, a dialdehyde derivative or a ketone derivative. The carotenoid derivative can be a derivative of any naturally occurring carotenoid, such as those found in tomatoes and other fruits and vegetables.

    摘要翻译： 本发明涉及一种化学预防和治疗癌症的方法，方法是通过施用包含类胡萝卜素衍生物的药物组合物，所述类胡萝卜素衍生物例如番茄红素，α-和β-胡萝卜素衍生物，八氢番茄红素，植物荧光素，叶黄素，玉米黄质，α-和 β-隐黄质，角黄素，虾青素或其他类胡萝卜素。 类胡萝卜素衍生物是类胡萝卜素氧化产物，优选为醛衍生物，二醛衍生物或酮衍生物。 类胡萝卜素衍生物可以是任何天然存在的类胡萝卜素的衍生物，例如在番茄和其他水果和蔬菜中发现的类胡萝卜素。

    Method and pharmaceutical preparations for reducing the activity of cells
    3.
    发明授权
    Method and pharmaceutical preparations for reducing the activity of cells 失效
    降低细胞活性的方法和药物制剂

    公开(公告)号：US5827900A

    公开(公告)日：1998-10-27

    申请号：US532263

    申请日：1995-09-22

    申请人： Joseph Levy ,  Yoav Sharoni

    发明人： Joseph Levy ,  Yoav Sharoni

    IPC分类号： A61K31/01 ,  A61K36/81 ,  A61P35/00

    CPC分类号： A61K31/01

    摘要： A method of reducing the activity of a cell comprises administering to the cell of a subject in need thereof, directly or systemically, a cell activity-reducing effective amount of lycopene. Pharmaceutical composition are derscribed, for inhibiting the growth of cancer cells, comprising as an active ingredient a cancer cell growth-inhibiting effective amount of lycopene.

    摘要翻译： 降低细胞活性的方法包括向有需要的受试者的细胞直接或全身施用减少细胞活性的有效量的番茄红素。 描述了用于抑制癌细胞生长的药物组合物，其包含作为活性成分的癌细胞生长抑制有效量的番茄红素。

    Method and compositions for preventing hormone induced adverse effects
    4.
    发明授权
    Method and compositions for preventing hormone induced adverse effects 有权
    用于预防激素诱发不良反应的方法和组合物

    公开(公告)号：US08669293B2

    公开(公告)日：2014-03-11

    申请号：US10240090

    申请日：2001-03-28

    申请人： Joseph Levy ,  Yoav Sharoni

    发明人： Joseph Levy ,  Yoav Sharoni

    IPC分类号： A01N31/04 ,  A61K31/07

    CPC分类号： A61K31/565 ,  A61K31/015 ,  A61K31/07 ,  A61K31/56 ,  A61K31/57 ,  A61K33/24 ,  A61K36/185 ,  A61K31/12 ,  A61K31/01 ,  A61K2300/00

    摘要： A method for preventing the adverse effects which may he associated with the administration of at least one hormone to a subject without detectable cancer comprising administering to such subject at least one carotenoid. The method of the instant invention can be utilized to prevent a variety of adverse effects associated with the administration of hormones, including for example, an increased risk for developing cancer. The instantly claimed method prevents such adverse effects without inhibiting the beneficial activity of the hormone. Further provided by the present invention are compositions which are useful for preventing the adverse effects associated with the administration of hormones. The compositions of the instant invention may be in unit dosage form suitable for daily administration to a human.

    摘要翻译： 一种用于预防可能与给予受试者的至少一种激素相关的不可检测的癌症的不良反应的方法，包括向所述受试者施用至少一种类胡萝卜素。 本发明的方法可以用于预防与施用激素相关的各种不良反应，包括例如增加发展中的癌症的风险。 立即要求保护的方法防止这种不利影响而不抑制激素的有益活性。 本发明还提供了可用于预防与激素施用相关的不良反应的组合物。 本发明的组合物可以是适合于每天给予人的单位剂量形式。

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
    6.
    发明授权
    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate 有权
    用于预测醋酸格拉默的反应的单核苷酸多态性的测定

    公开(公告)号：US09499868B2

    公开(公告)日：2016-11-22

    申请号：US14467954

    申请日：2014-08-25

    申请人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

    发明人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

    IPC分类号： A61K38/16 ,  C12Q1/68 ,  A61K45/06

    CPC分类号： C12Q1/6883 ,  A61K38/02 ,  A61K38/16 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156

    摘要： This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

    摘要翻译： 本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：1）鉴定人受试者是否为预测 通过在选自组1中的SNP的一个或多个单核苷酸多态性（SNP）上确定受试者的基因型来响应乙酸格拉司坦; 以及2）如果将受试者鉴定为乙酸格拉默的预测应答者，则向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

    FOOD CONTAINER WITH MEDIA PLAYER
    7.
    发明申请
    FOOD CONTAINER WITH MEDIA PLAYER 失效
    食品容器与媒体播放器

    公开(公告)号：US20120234704A1

    公开(公告)日：2012-09-20

    申请号：US13329997

    申请日：2011-12-19

    申请人： Joseph Levy ,  Marlon Carter

    发明人： Joseph Levy ,  Marlon Carter

    IPC分类号： B65D79/00

    CPC分类号： A45C15/00 ,  A45C11/20 ,  H04R1/028

    摘要： Embodiments of a food container including a media player are provided. In some embodiments, the food container has an exterior, and the food container comprises at least one compartment sized and dimensioned to accommodate food. Additionally, the food container includes a media player configured to play media content. The container and/or media player includes at least one device that serves as an input device to select media content in the media player of for later play and activation device to activate the play of the selected media content. In another embodiment the container and/or media player includes two devices, one to select media content and another to activate play of the selected media content. The media content can be, for example, a message from a parent or other meal maker to a child for later play by the child during the day.

    摘要翻译： 提供了包括媒体播放器的食物容器的实施例。 在一些实施例中，食物容器具有外部，并且食物容器包括尺寸和尺寸适于容纳食物的至少一个隔室。 另外，食品容器包括被配置为播放媒体内容的媒体播放器。 容器和/或媒体播放器包括用作输入设备的至少一个设备，用于选择媒体播放器中的媒体内容以供稍后播放和激活设备激活所选择的媒体内容的播放。 在另一个实施例中，容器和/或媒体播放器包括两个设备，一个用于选择媒体内容，另一个用于激活所选择的媒体内容的播放。 媒体内容可以是例如来自父母或其他膳食者给孩子的消息，以供儿童在白天玩耍。

    METHOD AND SYSTEM FOR ENHANCED BASIC SERVICE SET TRANSITION FOR A HIGH THROUGHPUT WIRELESS LOCAL AREA NETWORK
    10.
    发明申请
    METHOD AND SYSTEM FOR ENHANCED BASIC SERVICE SET TRANSITION FOR A HIGH THROUGHPUT WIRELESS LOCAL AREA NETWORK 审中-公开
    用于高速无线局域网的增强基本服务设置过渡的方法和系统

    公开(公告)号：US20070258384A1

    公开(公告)日：2007-11-08

    申请号：US11680892

    申请日：2007-03-01

    申请人： Mohammed Sammour ,  Marian Rudolf ,  Sudheer Grandhi ,  Joseph Levy

    发明人： Mohammed Sammour ,  Marian Rudolf ,  Sudheer Grandhi ,  Joseph Levy

    IPC分类号： H04J3/14

    CPC分类号： H04W36/24 ,  H04W28/22 ,  Y02D70/00 ,  Y02D70/142 ,  Y02D70/144 ,  Y02D70/23

    摘要： A wireless local area network (WLAN) includes at least one high throughput-enabled access point (AP) and at least one high throughput-enabled station (STA). A STA and a target AP communicate high throughput-related information and the STA performs a basic service set (BSS) transition to the target AP based on the high throughput-related information. The high throughput-related information may be included in an IEEE 802.11r, 802.11k, or 802.11v signaling message. The STA may send measurement reports for an extended range and a normal range of an AP separately, or may send a combined measurement report for an extended range and a normal range of an AP. A network management entity may obtain current status information of the STA and the AP regarding high throughput capabilities, features and parameters and selectively enable and disable at least one of the high throughput capabilities, features and parameters of the STA and the AP.

    摘要翻译： 无线局域网（WLAN）包括至少一个高吞吐量使能接入点（AP）和至少一个高吞吐量使能站（STA）。 STA和目标AP通信高吞吐量相关信息，并且STA基于高吞吐量相关信息执行到目标AP的基本服务集（BSS）转换。 高吞吐量相关信息可以包括在IEEE 802.11r，802.11k或802.11v信令消息中。 STA可以单独发送AP的扩展范围和正常范围的测量报告，或者可以发送AP的扩展范围和正常范围的组合测量报告。 网络管理实体可以获得关于高吞吐量能力，特征和参数的STA和AP的当前状态信息，并且选择性地启用和禁用STA和AP的高吞吐能力，特征和参数中的至少一个。